From 2011 to 2018, they worked as a Senior Scientist II at Inception Sciences, followed by a Senior Scientist II role at Pipeline Therapeutics from 2018 to 2020. Currently, they are …

May 6, 2022 · Jill Melissa Baccei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been …

Nov 24, 2020 · Abstract: Provided herein are compounds which are useful as antagonists of the muscarinic acetylcholine receptor M1 (mAChR M1); synthetic methods for making the …

Sep 3, 2019 · Jill Baccei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been …

Visual evoked potential (VEP) is a clinically translatable model used in patients with multiple sclerosis due to its ability to measure myelin damage of the visual pathway through the latency …

PIPE-307 is a potent, selective M1 antagonist (IC50 3.78nM, Fig 2A). PIPE-307 occupies 100% of M1 in the brain at 30mg/kg. No binding is observed in the cerebellum, an M1-poor region (Fig …

Michael M Poon1, Alexander Broadhead1, Geraldine Edu1, Ariana Lorenzana1, Kym I Lorrain1, Thomas Schrader1, Yifeng Xiong1, Jill Baccei1, Christopher Baccei1, Ari J Green2, Jonah R …

Find Jill Baccei's email HEADQUARTERS and direct dial phone number as Associate Director of Medicinal Chemistry at Autobahn therapeutics. View Autobahn therapeutics's business …

Discovery of a Novel M1 Selective Antagonist, PIPE-307, for the Treatment of Multiple Sclerosis Kym I Lorrain, Michael M Poon, Alexander Broadhead, Karin J Stebbins, Austin Chen, Jill …

Aug 5, 2024 · PIPE-307 is currently in Phase II clinical trials, offering hope for a groundbreaking treatment that could stop and even heal the damage caused by MS. This novel approach …